Eileen Parkes on Why Cancer Researchers Are Excited About STING Agonists
ONCOLOGY recently interviewed Dr. Eileen Parkes, whose laboratory studies the STING pathway, to find out why researchers are excited about targeting this pathway as a potential cancer therapy. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Eileen Parkes, MD, PhD Source Type: news

Nanoparticle therapy could deliver double blow to cancer
(University of East Anglia) A new cancer therapy using nanoparticles to deliver a combination therapy direct to cancer cells could be on the horizon.Using nanoparticles to get drugs directly into a tumor is a growing area of cancer research. The technology developed at UEA is the first of its kind to use nanoparticles to deliver two drugs in combination to target cancer cells. The therapy has been shown to make breast cancer and prostate cancer tumors more sensitive to chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2018 Category: International Medicine & Public Health Source Type: news

UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

Regeneron partners with bluebird on cancer therapies, invests $100 million
The company will use its VelociSuite platform in order to help find human antibodies as well as T cell receptors and bluebird will contribute its expertise in gene transfer and cell therapy (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 7, 2018 Category: Pharmaceuticals Source Type: news

Researchers use microparticles for targeted delivery of brain cancer therapy
Credit: Christine Daniloff/MIT A team of researchers from Brigham & Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences. The scientists created a test to check for a mutation linked to glioma and implanted microparticles that slowly elute drug over the course of several days or even weeks to treat the brain cancer. Get the full story at our sister site, ...
Source: Mass Device - August 7, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Pharmaceuticals Research & Development Brigham & Women's Hospital Massachusetts General Hospital Massachusetts Institute of Technology Source Type: news

Sensor could help doctors select effective cancer therapy
(Massachusetts Institute of Technology) MIT chemical engineers have developed a sensor that lets them see hydrogen peroxide inside cancer cells and determine whether they are responding to drugs that affect redox signaling. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 7, 2018 Category: Cancer & Oncology Source Type: news

Regeneron to invest $100 million in bluebird, jointly develop cancer therapies
Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer. (Source: Reuters: Health)
Source: Reuters: Health - August 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Medical News Today: New drug may improve liver cancer therapy
Hepatocellular carcinoma (liver cancer) is fast growing, has poor survival rates, and has inefficient current treatments. Can they be improved? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 6, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Mushrooms of the Far East hold promise for the anti-cancer therapy
Mushrooms from the Far East area contain the natural chemical compounds, which could be used for the design of the novel drugs with highly specific anti-tumor activities and low-toxicity. These compounds may offer new avenues for oncology, providing us with either stand-alone alternatives to chemotherapy, chemopreventive medicines, or drugs to be used in combination with other therapies. (Source: World Pharma News)
Source: World Pharma News - August 3, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AI speeds up radiation therapy planning
With a new artificial intelligence (AI) algorithm, planning for radiation therapy...Read more on AuntMinnie.comRelated Reading: Can AI best quantitative MRI in prostate lesions? Breast cancer follow-up imaging varies widely SNMMI: Early prostate cancer therapy extends lives SNMMI: Fluciclovine-PET changes prostate treatment SNMMI: New therapy aids patients with neuroendocrine tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 2, 2018 Category: Radiology Source Type: news

Mushrooms of the far east hold promise for the anti-cancer therapy
(Far Eastern Federal University) Mushrooms from the Far East area contain the natural chemical compounds, which could be used for the design of the novel drugs with highly specific anti-tumor activities and low-toxicity. These compounds may offer new avenues for oncology, providing us with either stand-alone alternatives to chemotherapy, chemopreventive medicines, or drugs to be used in combination with other therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2018 Category: Cancer & Oncology Source Type: news

Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers
This research article found patients who received CM were more likely to refuse additional conventional cancer treatment (surgery/chemo or radio or hormone therapy) and had higher risk of death. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 1, 2018 Category: Consumer Health News Source Type: news

Novel drug cocktails strengthen targeted cancer therapies while lessening side effects
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Mount Sinai researchers have discovered that certain drug cocktails help targeted therapies attack cancer more efficiently while lessening common side effects, according to a study published today in Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 1, 2018 Category: Cancer & Oncology Source Type: news

Medical researchers from MSU suggested a new approach of targeted cancer therapy
(Lomonosov Moscow State University) A team from the Faculty of Medicine, MSU has analysed a link between the p53 protein, tumor dissemination and 'cell suicide' and discussed possible approaches to predict metastases development and their treatment. They also discussed new chemical compounds that might influence the process of metastasis. The study was supported by a grant from Russian Science Foundation (RSF). The results were published in the Cancers journal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2018 Category: International Medicine & Public Health Source Type: news

FDA approves Progenics' drug for rare tumors
The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors, pheochromocytoma or paraganglioma, and require anti-cancer therapy (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 31, 2018 Category: Pharmaceuticals Source Type: news

Nanobiotix inks $47m financing to support nanomedicine development
Nanobiotix (PAR:NANO.PA) inked a non-dilutive financial deal with the European Investment Bank last week to support the development of its nanoparticle-based cancer therapies. The Paris, France-based company said it landed a five-year loan to borrow up to €40 million ($46.7 million) contingent upon a set of performance milestones. Get the full story at our sister site, Drug Delivery Business News. The post Nanobiotix inks $47m financing to support nanomedicine development appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Funding Roundup Oncology Pharmaceuticals Wall Street Beat nanobiotix Source Type: news

FLT-PET points toward survival for glioblastoma patients
PET scans with the radiotracer F-18 fluorothymidine (FLT) can help determine...Read more on AuntMinnie.comRelated Reading: SNMMI: PET, MRI may predict pediatric brain tumor outcomes FDG-PET/CT beats FLT-PET/CT for differentiated thyroid cancer FLT-PET could help predict outcome in head and neck cancer JNM: FLT-PET aids prognosis of glioma patients FLT-PET helps predicts cancer therapy results (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 26, 2018 Category: Radiology Source Type: news

New strategy for cancer therapy spells double trouble for tumors
(Scripps Research Institute) The study, published recently in Nature Communications, shows that a molecule in cells, called Rad52, repairs special kinds of damaged DNA that accumulate in some cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 25, 2018 Category: Cancer & Oncology Source Type: news

Complementary Medicine Use Ups Refusal of Usual Cancer Therapy
FRIDAY, July 20, 2018 -- Patients with cancer who receive complementary medicine (CM) are more likely to refuse conventional cancer treatment (CCT), according to a study published online July 19 in JAMA Oncology. Skyler B. Johnson, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2018 Category: Pharmaceuticals Source Type: news

Complementary cancer therapies linked to reduced survival
Cancer patients who receive complementary therapies are more likely to shun proven treatments, a study finds. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 19, 2018 Category: Consumer Health News Source Type: news

Alternative cancer therapies linked to reduced survival
Cancer patients who receive alternative therapies are more likely to shun proven treatments, a study finds. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 19, 2018 Category: Consumer Health News Source Type: news

How Complementary Cancer Therapies Can Increase Risk of Early Death
People diagnosed with cancer have a multitude of treatment options, many of which are standard therapies that have been well-studied to improve their chances of surviving their disease or avoiding recurrence. But people are increasingly also folding in complementary medicine approaches — which include nutrients, herbal remedies and other so-called natural supplements — with their cancer treatment regimes. While these are not nearly as well-studied as conventional therapies like surgery, radiation and chemotherapy, many people rely on them because they believe they can improve their chances of surviving their ca...
Source: TIME: Health - July 19, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthytime Source Type: news

VA, IBM Watson Health extend precision cancer partnership
The Department of Veterans Affairs and IBM Watson Health have announced a one-year extension to an ongoing public-private partnership applying the AI company ’s technology to genomic data for cancer therapy. (Source: mobihealthnews)
Source: mobihealthnews - July 19, 2018 Category: Information Technology Source Type: news

Association of complementary medicine, cancer treatment, survival
(JAMA Network) The use of complementary medicine by patients with four common cancers (breast, prostate, lung or colorectal) was associated with refusal of conventional cancer treatment and with a greater risk of death, although the difference in survival may be alleviated by adherence to all recommended conventional cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2018 Category: Cancer & Oncology Source Type: news

Cannabinoids may have a vast array of anti-cancer effects
(Wiley) Previous research has shown that cannabinoids can help lessen side effects of anti-cancer therapies. Now a new British Journal of Pharmacology review has examined their potential for the direct treatment of cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2018 Category: International Medicine & Public Health Source Type: news

Insurers And Government Are Slow To Cover Expensive CAR-T Cancer Therapy
Treatment costs for the immunotherapy can run to more than $1 million. Some state Medicaid programs aren't paying for the treatment, and Medicare's complicated payment rates have hospitals worried.(Image credit: Fanatic Studio/Collection Mix: Subjects RF/Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - July 17, 2018 Category: Consumer Health News Authors: Michelle Andrews Source Type: news

Rheumatic Adverse Events on the Rise with Cancer Therapies
(MedPage Today) -- With immune checkpoint inhibition, rheumatic adverse events may become more common than RA (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - July 15, 2018 Category: Rheumatology Source Type: news

Solved protein puzzle opens door to new design for cancer drugs
(Oregon State University) Researchers at have solved a longstanding puzzle concerning the design of molecular motors, paving the way toward new cancer therapies. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 12, 2018 Category: Biology Source Type: news

Medical News Today: Keto diet could make cancer therapy more effective
A new study suggests that the ketogenic diet, which is very low in carbohydrates but high in fats, may give cancer therapy a much-needed boost. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 10, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Laetrile Amygdalin Alternative Cancer Therapy
Laetrile (Amygdalin) as Alternative Cancer Therapy (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 10, 2018 Category: General Medicine Source Type: news

Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to“off the shelf” cancer therapies that aren’t patient-specific. (Source: The Scientist)
Source: The Scientist - July 6, 2018 Category: Science Tags: News & Opinion Source Type: news

Ultra-quick electric pulses KILLING cancer cells – Time for the world to pay close attention
(Natural News) For more than a decade, a team of cancer researchers at Old Dominion University (ODU) in Norfolk, Virginia have been studying a new type of cancer therapy that utilizes nano-second stimulation by ultra-fast electrical pulses to kill tumor cells, and now, after testing it out on mice, it’s working. Generating about 3 million... (Source: NaturalNews.com)
Source: NaturalNews.com - July 5, 2018 Category: Consumer Health News Source Type: news

Can deep learning monitor lesions on F-18 NaF PET/CT?
Deep learning can classify bone lesions found on F-18 sodium fluoride (NaF)...Read more on AuntMinnie.comRelated Reading: Group uses AI to assess mammo interpretation bias SNMMI: AI enables stress-first SPECT MPI protocol SNMMI: Early prostate cancer therapy extends lives SNMMI: AI can predict survival in sarcoma patients AI algorithm can classify bone lesions on PET/CT images (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 5, 2018 Category: Radiology Source Type: news

Novel nanoSPECT/CT radionuclide could aid cancer therapy
Swedish and Dutch researchers are reporting early progress in combining nanoSPECT/CT...Read more on AuntMinnie.comRelated Reading: SNMMI: Early prostate cancer therapy extends lives SNMMI: New therapy aids patients with neuroendocrine tumors Novel PET tracer shows promise for neuroendocrine tumors PET tracer may aid diagnosis of inflammatory bowel disease New therapeutic agent could treat prostate cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 3, 2018 Category: Radiology Source Type: news

Cell Signaling and Metabolism: Bridging a Gap in Cancer Therapies
The Scientist is bringing together a panel of experts to discuss their research into an exciting and recently acknowledged hallmark of cancer. (Source: The Scientist)
Source: The Scientist - June 29, 2018 Category: Science Tags: Sponsored Webinars Source Type: news

New prostate cancer therapy may delay need for testosterone use
A new radiotherapy treatment for advanced prostate cancer may offer patients a possibility to delay hormone treatment, results from a small-scale clinical trial published inEuropean Urology suggest.ABC News (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 29, 2018 Category: Endocrinology Source Type: news

Otago researchers' discovery unlocks secrets behind cancer drug resistance
(University of Otago) University of Otago research provides insights into an underlying mechanism that could explain why new cancer therapies to help treat metastatic melanoma do not always work on patients, paving the way for predicting which patients will benefit from certain drugs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 29, 2018 Category: International Medicine & Public Health Source Type: news

Toxicities of the New Cancer Therapies
(MedPage Today) -- Julie Brahmer, MD, on new guidelines for managing side effects (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 27, 2018 Category: Hematology Source Type: news

SNMMI: AI enables stress-first SPECT MPI protocol
PHILADELPHIA - Artificial intelligence (AI) analysis of stress SPECT myocardial...Read more on AuntMinnie.comRelated Reading: SNMMI: Early prostate cancer therapy extends lives SNMMI: New therapy aids patients with neuroendocrine tumors SNMMI: AI can predict survival in sarcoma patients SNMMI 2018: A year of promotion and ongoing challenges ASNC releases new guidelines for SPECT MPI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 27, 2018 Category: Radiology Source Type: news

Immuno-Oncology Conference 2018
26 - 27 September, London, UK. Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress. (Source: World Pharma News)
Source: World Pharma News - June 27, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

SNMMI: Fluciclovine-PET changes prostate treatment
PHILADELPHIA - With the addition of F-18 fluciclovine to PET/CT scans, clinicians...Read more on AuntMinnie.comRelated Reading: SNMMI: Early prostate cancer therapy extends lives SNMMI: Molecular imaging method monitors gene therapy Blue Earth promotes results for PET/CT agent Blue Earth touts addition of Axumin to NCCN guidelines Novel PET tracer aids recurrent prostate cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 26, 2018 Category: Radiology Source Type: news

SNMMI: Early prostate cancer therapy extends lives
PHILADELPHIA - Providing lutetium-177 prostate-specific membrane antigen radioligand...Read more on AuntMinnie.comRelated Reading: Annals: Overdiagnosis must be better defined SNMMI: New therapy aids patients with neuroendocrine tumors SNMMI: AI can predict survival in sarcoma patients SNMMI 2018: A year of promotion and ongoing challenges Faster MRI protocol avoids unneeded prostate biopsies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 26, 2018 Category: Radiology Source Type: news

When one drug fails, a new door opens for cancer treatment
(Thomas Jefferson University) As cancers find ways to bypass a new therapy, researchers discover the tumor also develops an Achilles heel that can be hit with a different cancer therapy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 26, 2018 Category: Biology Source Type: news

Medical News Today: New 'potential target' for cancer therapy found
A protein that causes cancer cells to release tiny bags of proteins and molecules that help tumor progression may be a new treatment target, a study says. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 22, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

New Horizons in Systemic Anti-cancer Therapy in Older People New Horizons in Systemic Anti-cancer Therapy in Older People
What are the specific challenges faced by older persons with regards to systemic anti-cancer therapy, and how can we improve cancer therapeutics for this population?Age and Ageing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

An emerging drug discovery approach to combat cancer
(Bentham Science Publishers) This review paper will cover recent advances in the development of chemotherapeutic agents against several metabolic targets for cancer therapy, including glucose transporters, hexokinase, pyruvate kinase M2, glutaminase, and isocitrate dehydrogenase. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 21, 2018 Category: Biology Source Type: news

Kimmel Cancer Center forms partnership to expand access to clinical trials
Jefferson Health's Sidney Kimmel Cancer Center is teaming up with the Sarah Cannon Research Institute in a collaboration designed to expand clinical trial offerings to patients in the Philadelphia area. Sarah Cannon, based in Nashville, developed the first community-based drug development program in the country. The organization has conducted more than 300 first-in-human studies and has been a clinical trial leader in the majority of approved cancer therapies over the last decade. Through its net work… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 20, 2018 Category: Health Management Authors: John George Source Type: news

Kimmel Cancer Center forms partnership to expand access to clinical trials
Jefferson Health's Sidney Kimmel Cancer Center is teaming up with the Sarah Cannon Research Institute in a collaboration designed to expand clinical trial offerings to patients in the Philadelphia area. Sarah Cannon, based in Nashville, developed the first community-based drug development program in the country. The organization has conducted more than 300 first-in-human studies and has been a clinical trial leader in the majority of approved cancer therapies over the last decade. Through its net work… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 20, 2018 Category: Biotechnology Authors: John George Source Type: news

Latecomer Sanofi looks to catch next wave of cancer therapies
PARIS (Reuters) - Sanofi missed the boat on immune system-boosting cancer drugs. Now it's trying to catch up. (Source: Reuters: Health)
Source: Reuters: Health - June 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche Is Willing to Pay a Pretty Penny for the Rest of Foundation Medicine
Roche already owns a majority stake in Foundation Medicine, but now the Swiss company wants to buy the rest of the genomic diagnostics company, and it is willing to pay a pretty penny to do so. Roche agreed to pay $137 a share to buy the rest of Cambridge, MA-based Foundation Medicine, a $2.4 billion transaction that values the company at $5.3 billion. The offer price represents a 29% premium over Foundation Medicine's closing stock price Monday. The deal is expected to close during the second half of the year. The deal marks a turning point in Roche's relationship with Foundation Medicine, which dates back to January...
Source: MDDI - June 19, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news